Infections, connective tissue diseases and vasculitis

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Avcin, Tadej ^a   Canova, Mariagrazia ^b   Guilpain, Philippe ^c   Guillevin, Loïc ^c   Kallenberg, Cees G M ^d   Tincani, Angela ^e   Tonon, Michele ^b   Zampieri, Sandra ^b   Doria, Andrea ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^b UNIVERSITY OF PADOVA   (Italy)

^c Université Paris Descartes ^*  (France)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Antiphospholipid antibody syndrome; Immunosuppressants; Infections; Polymyositis dermatomyositis; Systemic lupus erythematosus; Vasculitis; Wegener's granulomatosis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PNEUMOCOCCUS VACCINE; PREDNISONE; RIBAVIRIN; RITUXIMAB; STEROID;

ANTIBIOTIC PROPHYLAXIS; ANTIPHOSPHOLIPID SYNDROME; BACTERIAL INFECTION; CONNECTIVE TISSUE DISEASE; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENETIC PREDISPOSITION; HEPATITIS B; HEPATITIS C; HERPES VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION; INFECTION RISK; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OPPORTUNISTIC INFECTION; PARASITOSIS; PARVOVIRUS; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; VASCULITIS; VIRUS INFECTION; VIRUS REPLICATION; WEGENER GRANULOMATOSIS;

CONNECTIVE TISSUE DISEASES; HUMANS; INFECTION; VASCULITIS;

EID: 42549167072     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. KIM B, KAISTHA SD, ROUSE BT: Viruses and autoimmunity. Autoimmunily 2006; 39: 71-7.
2. PENG Y, MARTIN DA, KENKEL J, ZHANG K, OGDEN CA, ELKON KB: Innate and adaptive immune response to apoptotic cells. J Auto-immun 2007; 29: 303-9.
3. MICHLEWSKA, MCCOLL A, ROSSI AG, MEGSON IL, DRANSFIELD I: Clearance of dying cells and autoimmunity. Autoimmunity 2007; 40: 267-73.
4. RYAN KR, PATEL SD, STEPHENS LA, ANDERTON SM: Death, adaptation and regulation: The three pillars of immune tolerance restrict the risk of autoimmune disease caused by molecular mimicry. J Autoimmun 2007; 29: 262-71.
5. SOULAS P, WOODS A, JAULHAC B et al.: Autoantigen, innate immunity, and T cells cooperate to break B cell tolerance during bacterial infection. J Clin Invest 2005; 115: 2257-67.
6. ZANDMAN-GODDARD G, SHOENFELD Y: Infections and SLE. Autoimmunity 2005; 38: 473-85.
7. AL-RAYES H, AL-SWAILEM R, ARFIN M, SOBKI S, RIZVI S, TARIQ M: Lupus around the world: Systemic lupus erytherAatosus and infections: a retrospective study in Saudis. Lupus 2007; 16: 755-63.
8. POOLE BD, SCOFIELD RH, HARLEY JB, JAMES JA: Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006; 39: 63-70.
9. HARLEY JB, HARLEY ITW, GUTHRIDGE JM, JAMES JA: The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 2006; 15: 768-777.
10. MCCLAIN MT, HEILEN LD, DENNIS GJ, ROEBUCK J, HARLEY JB, JAMES JA: Rearly events in 1upus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11: 85-9.
11. JAMES J, HARLEY JB, SCOFIELD RH: Role of Epstein-Barr Virus in systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18: 462-7.
12. BENNETT L, PALUCKA AK, ARCE E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 17: 711-23.
13. MARSHAK-ROTHSTEIN A: Toll-like Receptors in Systemic Autoimmune Disease. Nature Rev Immunol 2006; 6: 823-35.
14. SEKIGAWA I,IKAWASAKI M, OGASAWARA A et al.: DNA methylation: its contribution to systemic lupus erythematosus. Clin Exp Med 2006; 6: 69-106.
15. ALARCÒN GS: Infections in systemic connective tissue diseases: Systemic lupus erythematosus, sclerodermia, and polymyositis/ dermatomyositis. Infect Dis Clin N Am 2006; 20: 849-75.
16. SARZI-PUTTINI P, ATZENI F, IACCARINO L, DORIA A: Environment and systemic lupus erythematosus: An overview. Autoimmunity 2005: 38: 465-72.
17. BOSCH X, GUILABERT A, PALLARÉS L et al.: Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients. Lupus 2006; 15: 584-9.
18. DORIA A, IACCARINO L, GHIRARDELLO A et al.: Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 1497-9.
19. DIRIA A, BRIANI C: Lupus: improving long-term prognosis. Lupus 2008: In press.
20. DORIA A, ARIENTI S, RAMPUDDA M, CANOVA M, TONON M, SARZI-PUTTINI P: Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008, 7: 192-7.
21. KURUMA KAM, BORBA EF, LOPES MH, DE CARVALHO JF, BONFÁ E: Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16: 350-4.
22. GALEAZZI M, BELLISAI F, MANGANELLI S, MOROZZI G, SEBASTIANI GD: Cyclosporine, A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006; 5: 493-8.
23. DORIA A, IACCARINO L, ARIENTI S et al.: Mycophenolate mofetil and systemic lupus erythematosus. Lupus 2006; 15 (Suppl.): 44-54.
24. IACCARINO L, RAMPUDDA ME, CANOVA M, DELLA LIBERA S, SARZI-PUTTINI P, DORIA A: MycophenWlate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmunity Rev 2007 6: 190-5.
25. O'NEILL SG, ISENBERG DA: Immunizing patients with systemic lupus erythematosus: A review of effectiveness and safety. Lupus 2006; 15: 778-83.
26. ZAMPIERI S, GHIRARDELLO A, IACCARINO L et al.: Polymyositis-dermatomyositis and infections. Autoimmunity 2006; 39: 191-6.
27. LEFF RL, BURGESS SH, MILLER FW et al.: Distinct seasonal patterns in the onset of adult inflammatory myopathy in patients with anti Jo-1 and anti-Signal recognition particle autoantibodies. Arthritis Rheum 1991; 34: 1391-7.
28. TAM PE, SCHIMIDT AM, YTTERBERG SR, MESSNER RP: Duration of virus persistence and its relationship to inflammation during chronic phase of coxsackievirus B1-induced murine polymyositis. J Lab Clin Med 1994; 123: 346-56.
29. CRONIN ME, LOVE LA, MILLER FW, MCCLINTOCK PR, PLOTZ PH: The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization. J Exp Med 1988; 168: 1639-48.
30. WHITTON JL, FEUER R: Myocarditis, microbes and autoimmunity. Autoimmunity 2004; 37: 375-86.
31. ZAMPIERI S, GHIRARDELLO A, IACCARINO L, TARRICONE E, GAMBARI PF, DORIA A: Anti-Jo-1 antibodies. Autoimmunity 2005; 38: 73-8.
32. GHIRARDELLO A, ZAMPIERI S, IACCARINO L et al.: Anti-Mi-2 antibodies. Autoimmunity 2005; 38: 79-83.
33. BOLZ DD, WEIS JJ: Molecular mimicry tP Borrelia burgdorferi: pathway to autnimmunity? Autoimmunity 2004; 37: 387-92.
34. ALBANI S: Infection and molecular mimicry in autoimmune disease ofchildhood. Clin Exp Rheumatol 1994; 12 (Suppl. 10): S35-S41.
35. YOUSELF GE, ISENBERG DA, MOWBRAY JF: Detection of enterovirus specific RNA sequences in muscle biopsy specimens from patients with adult onset of myositis. Ann Rheum Dis 1990; 49: 310-5.
36. MOORE EC, COHEN F, DOUGLAS SD, GUTTA V: Staphyolococcal infections in childhood dermatomyositis-association with the development of calcinosis, raised IgE concentration and granulocyte chemotactic defect. Ann Rheum Dis 1992; 51: 378-83.
37. MARIE I, HACHULLA E, CHERIN P et al.: Opportunistic infection in polymyositis and dermatomyositis. Arthitis Rheum 2005; 53: 155-65.
38. NAGAOKA S, TANI K, ISHIGATSUBO Y et al.: Herpes zoster in patients with polymyositis and dermatomyositis. Kansenshogaku Zasshi. 1990; 64: 1394-9.
39. KOIKE T, BOHGAKI M, AMENGUAL O, ATSUMI T: Antiphospholipid antibodies: Lessons from the bench. J Autoimmun 2007; 28: 129-33.
40. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295-306.
41. ASHERSON RA, FRANCÈS C, IACCARINO L et al.: The antiphospholipid antibody syndrome: Diagnosis, skin manifestations and current therapy. Clin and Exp Rheumatol 2006; 24 (Suppl. 40): S46-S51.
42. CERVERA R, ASHERSON RA, ACEVEDO ML et al.: Antiphospholipid syndrome associated with infections: Clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004, 63:1312-7.
43. SHOENFELD Y, BLANK M, CERVERA R et al.: Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006, 65: 2-6.
44. LEVY Y, ALMOG O, GORSHTEIN A, SHOENFELD Y: The environment and antiphospholipid syndrome. Lupus 2006; 15: 784-90.
45. VON LANDENBERG P, LEHMANN HW, MODROW S: Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev 2007; 6: 278-85.
46. AVCIN T, TOPLAK N: Antiphospholipid antibodies in response to infection. Current Rheum Reports 2007; 9: 212-18.
47. GUGLIELMONE H, VITOZZI S, ELBARCHA O, FERNANDEZ E: Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis 2001, 60: 500-4.
48. KALT M, GERTNER E: Antibodies to beta 2-glycoprotein I and cardiolipin with symptoms suggestive of systemic lupus erythematosus in parvovirus B19 infection. J Rheumatol 2001, 28: 2335-6.
49. BAKSHI M, KHEMANI C, VISHWANATHAN V, ANAND RK, KHUBCHANDANI RP: Mycoplasma pneumonia with antiphospholipid antibodies and a cardiac thrombus. Lupus 2006; 15: 105-6.
50. HOJNIK M, GILBURD B, ZIPOREN L et al.: Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: Analysis of anticardiolipin antibodies in leprosy. Lupus 1994, 3: 515-21.
51. MARTINUC-POROBIC J, AVCIN T, BOZIC B et al.: Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol 2005, 142: 377-80.
52. ESPINOSA G, BUCCIARELLI S, CERVERA R, GÓMEZ-PUERTA JA, FONT J: Laboratory studies on pathophysiology of the catastrophic antiphospholipid sindrome. Autoimmun Rev 2006; 6: 68-71.
53. CERVERA R, KHAMASHTA M, SHOENFELD Y et al: Morbidity and Mortality in the Antiphospholipid Syndrome during a 5-year period: A Multicenter Prospective Study of 1000 patients. Submitted for publication.
54. VON LANDENBERG P, LEHMANN HW, KNOLL A et al.: Antiphosphohpid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003, 48: 1939-47.
55. SOMER T, FINEGOLD SM: Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 1995; 20: 101-36.
56. PAGNOUX C, COHEN P, GUILLEVIN L: Vasculitides secondary to infections. Clin Exp Rheumatol 2006; 24 (Suppl. 41): S071-S081.
57. MAKSIMOWICZ-MCKINNON K, HOFFMAN GS: Large vessel vasculitis. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S58-S59.
58. GUILLEVIN L, MAHR A, CALLARD P et al.: Hepatitis B virus-associated polyarterifis nodosa: Clinical characteristics, outcome and impact of treatment in 115 patients. Medicine 2005; 84: 313-22.
59. YEUNG RS: Lessons learned from an animal model of Kawasaki disease. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S69-S71.
60. LLOYD AJ, WAIKER C, WILKINSON M: Kawasaki disease: is it caused by an infectious agent? Br J Biomed Sci 1001; 58: 122-8.
61. MEISSNER HC, LEUNG DY: Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr Infect Dis J 2000; 19: 91-4.
62. SAADOUN D, LANDAU DA, CALABRESE LH, CACOUB PP: Hepatitis C-associated mixed cryoglobulinemia: A crossroad between autoimmunity and lymphoproliferation. Rheumatology 2007; 46: 1234-42.
63. FERRI C, ANTONELLI A, MASCIA MT et al.: B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007; 7: 114-20.
64. DILLON MJ: Henoch-Schonlein purpura: recent advances. Clin and Exp Rheumatol 2007; 25 (Suppl. 44): S66-S68.
65. MAHR AD, NEOGI T, MERKEL PA: Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin and Exp Rheumatol 2006; 24 (Suppl. 41): S82-S91.
66. JARROUSSE B, GUILLEVIN L, BINDI P et al.: Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993; 11: 615-21.
67. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
68. GUILPAIN P, CRANSEAUD Y, TAMBY MC et al.: Pathogenesis of primary systemic vasculitides (I): ANCA-positive vasculitides. Presse Med 2005; 34: 1013-22.
69. STEGEMAN CA, TERVAERT JW, SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus. and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-7.
70. STEGEMAN CA, TERVAERT JW, DE JONG PE, KALLENBERG CG: Trimethoprim-sulfam-ethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20.
71. + T lymphocytes in response to Staphylococcus aureus in patients with Wegener's granulomatosis. Scand J Immunol 1999; 49: 585-94.
72. POPA ER, STEGEMAN CA, ABDULAHAD WH et al.: Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46: 1029-33.
73. TERVAERT JW, POPA ER, BOS NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 1999; 11: 24-33.
74. GRUNEWALD J, HALAPI E, WAHLSTROM J et al.: T-cell expansions with conserved T-cell receptor beta chain motifs in the peripheral blood of HLA-DRB1*0401 positive patients with necrotizing vasculitis. Blood 1998; 92: 3737-44.
75. PENDERGRAFT WF 3rd PRESTON GA, SHAH RR et al.: Autoinimunity is triggered by cPR-3 (105-201), a protein complementary to human autoantigen proteinase-3. Nature Medicine 2004; 10: 72-9.